Rafivirumab, formerly known as CR57, represents a intriguing therapeutic designed for VEGF receptor 2 , VEGFR2. Its evolution from initial research involved a substantial commitment by Nektar , subsequent licensing with BMS . The therapeutic program has encompassed multiple trial assessments, mai